Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature

Atezolizumab is a monoclonal antibody that targets programmed death ligand-1. Treatments with this drug may cause immune-related adverse events by creating an exaggerated inflammatory response. The most common side effects are fatigue, rash, and gastrointestinal symptoms. Cases of central nervous sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Laserna, Andrés, Tummala, Sudhakar, Patel, Neel, El Hamouda, Diaa Eldin Mohamed, Gutiérrez, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088478/
https://www.ncbi.nlm.nih.gov/pubmed/30116528
http://dx.doi.org/10.1177/2050313X18792422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088478/
https://www.ncbi.nlm.nih.gov/pubmed/30116528
http://dx.doi.org/10.1177/2050313X18792422

Ejemplares similares